Major breakthrough in gene editing technology, multiple listed companies are making arrangements.

A research team from Uppsala University in Sweden published a study in the New England Journal of Medicine on August 6, stating that the world's first donor pancreatic islet beta cells obtained through CRISPR-Cas gene editing technology have successfully survived and functioned in Type 1 diabetes patients for up to 12 weeks without the use of immunosuppressive agents. This technology brings hope for curing Type 1 diabetes. In the A-share market, there are more than 20 listed companies involved in gene editing technology. In terms of institutional attention, according to data from Data Bao, a total of 21 gene editing concept stocks have obtained an "active" rating from institutions, with Stable Medical being the most favored by institutions, with a total of 27 research reports mentioning the stock.